2025-09-07 於2025月09月02日

Driving Innovation and Collaboration in Healthcare: Insights from Regulatory Advances, Cutting-Edge Therapies, and Community Engagement

Welcome to this issue of Hong Kong Pharmaceutical Journal, where we showcase a collection of articles that reflect the dynamic and evolving landscape of healthcare. From regulatory advancements and cutting-edge therapies to public health strategies and professional collaboration, this edition offers valuable insights into addressing contemporary challenges and shaping the future of healthcare delivery.

Our first article explores the potential for Hong Kong to establish an expedited over-the-counter (OTC) drug registration pathway, drawing on lessons from the United States and Canada. The article highlights the benefits of enhanced regulatory efficiency, reduced costs for manufacturers and improved public health outcomes through greater access to safe OTC medications. However, it also underscores the challenges, including quality control, safety concerns and consumer education. The critical role of pharmacists in this transition, alongside stakeholder collaboration, is emphasized as a cornerstone for success. This piece serves as a timely discussion on how regulatory innovation can balance accessibility and safety in healthcare.

Next, we delve into the groundbreaking field of chimeric antigen receptor T-cell (CAR-T) therapy, a revolutionary approach to treating relapsed/refractory large B-cell lymphoma. The review focuses on tisagenlecleucel and axicabtagene ciloleucel, examining their mechanisms of action, efficacy, safety profiles and expanding clinical applications. With only tisagenlecleucel currently registered in Hong Kong, the article discusses how emerging data and comparative analyses may influence regulatory and clinical decisions, including the potential expansion of axicabtagene ciloleucel’s role. This review not only highlights the promise of CAR-T therapy but also underscores the importance of monitoring and managing adverse reactions to ensure patient safety.

Addressing a persistent public health challenge, our third article focuses on chronic hepatitis B (CHB) and the untapped potential of community pharmacies in screening and management. Despite global efforts to eliminate hepatitis B by 2030, gaps in screening and linkage to care remain significant, particularly in high-prevalence regions like Hong Kong. Drawing on international case studies and local pilot programs, the article outlines a framework for expanding the role of pharmacists in hepatitis B care. Recommendations include regulatory reform, standardized protocols and integration with primary healthcare systems. This piece advocates for leveraging community pharmacies as accessible, person-centered hubs for preventive care and chronic disease management.

Finally, we present a report on the PHARM+Excellence 2025 conference, a landmark event that brought together healthcare professionals, academics, policymakers and social service providers to advance the role of pharmacists in primary healthcare. Under the theme “Shaping the Future of Primary Healthcare Pharmacy: Quality Standards, Research, and Interprofessional Collaboration,” the conference emphasized quality standards, research and interprofessional collaboration. The event served as a catalyst for actionable strategies, including policy translation, capacity building, stakeholder engagement and international collaboration. This report marks a milestone in elevating the role of pharmacists within primary healthcare and signals a path toward more integrated, patient-centered care.

Together, these articles reflect the multifaceted nature of healthcare innovation, from regulatory frameworks and advanced therapies to community-based interventions and professional development. They highlight the importance of collaboration, evidence-based practice and adaptability in addressing both current and emerging healthcare challenges. As we navigate this ever-evolving landscape, these contributions offer valuable guidance for policymakers, practitioners and researchers alike.

We hope this issue inspires thoughtful discussion and action, driving progress toward a healthier and more equitable future for all. Thank you for joining us on this journey of discovery and innovation.

May PS Lam 

Editor-in-Chief 

5 September 2025